Katja Wesner, Christoph Hiemke, Niels Bergemann, Karin M Egberts, Stefanie Fekete, Manfred Gerlach, Ursula Havemann-Reinecke, Xenija M Lense, Thomas G Riemer, Georgios Schoretsanitis, Manfred Uhr, Gerald Zernig, Gerhard Gründer, Xenia M Hart
Objective: Aiming at revising the therapeutic reference range for olanzapine, the present study highlights the association between blood olanzapine levels, clinical effects, and dopamine D2 -receptor occupancy for oral and long-acting injectable (LAI) formulations. Data Sources: Databases were systematically searched for randomized controlled trials (RCTs) and uncontrolled trials concerning blood olanzapine levels in relation to clinical outcomes or D2 -receptor occupancy using MEDLINE (PubMed), Web of Science, PsycINFO, and Cochrane Library (March 2021, updated in December 2021)...
July 19, 2023: Journal of Clinical Psychiatry